ClinicalTrials.gg
CompletedNCT05755906LITHOSUpdated Jan 28, 2026Results posted

A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

A Phase 3 interventional study of BFF MDI 160/9.6 μg BID (320/19.2μg/day) and BD MDI 160 μg BID (320 μg/day) in Asthma, sponsored by AstraZeneca. Completed at 104 sites in 7 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
374
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
32nd of 108
374 · median 124
Started
2023
with 1 other
Phase 3
51 of 110
3 open now
Registered
105th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 32nd largest by enrollment of the 108 interventional ones that give a count, is one of 2 that started in 2023, is one of 51 in phase 3, and was the 105th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

This is a 12-week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler relative to budesonide metered dose inhaler in adults and adolescents with inadequately controlled asthma.

Read the detailed description

This is a Phase III, randomized, double-blind, parallel group, multicenter study comparing Budesonide and Formoterol Fumarate Metered Dose Inhaler (BFF MDI) 160/9.6 μg twice daily (BID) to Budesonide MDI 160 μg (BD MDI), over 12 weeks. The study population will consist of adult and adolescent participants with asthma who remain inadequately controlled, as demonstrated by an Asthma Control Questionnaire (ACQ)-7 total score ≥1.5, despite treatment with low dose inhaled corticosteroid (ICS) or ICS/long-acting beta2-agonist (LABA). This study is to assess the benefits and safety of BFF MDI on lung function and asthma health-related quality of life.

This study will be conducted at approximately 90 sites worldwide and will randomize approximately 340 adult and adolescent participants.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 12 to 80 years of age, male and female, \<40 kg/m2; females of should be using highly effective .
  2. Participants who have a documented history of physician-diagnosed asthma ≥ 6 months prior to Visit 1, according to GINA guidelines [GINA 2021]. Healthcare records for one year prior to Visit 1 must be provided for adolescent participants (12 to \< 18 years of age) to ensure consistent evaluation and follow-up of treatment in those participants.
  3. Participants who have been regularly using a stable daily ICS or an ICS/LABA regimen (including a stable ICS dose), with allowed ICS doses, for at least 8 weeks prior to Visit 1.
  4. ACQ-7 total score ≥ 1.5 at Visits 1 and 4.
  5. A pre-bronchodilator/pre-dose \< 90% predicted normal value at Visits 1, 2, and 3 and a pre-dose FEV1 of 50% to 90% at Visit 4 (pre-randomization).
  6. Reversibility to albuterol, defined as a post-albuterol increase in FEV1 of ≥ 12% and ≥ 200 mL for participants ≥ 18 years of age OR a post-albuterol increase in FEV1 of ≥ 12% for participants 12 to \< 18 years of age either in the 12 months prior to Visit 1 or at Visit 2 or Visit 3, if repeat testing is necessary.
  7. A pre-bronchodilator/pre-dose FEV1 at Visits 2, 3, and 4 that has not changed 20% or more (increase or decrease) from the pre-bronchodilator/pre-dose FEV1 recorded at the previous visit.
  8. Asthma stability during run-in based on Investigator discretion using the symptom worsening assessment defined in Section 8.1.2.8 as a guideline.
  9. Willing and, in the opinion of the Investigator, able to adjust current asthma therapy, as required by the protocol.
  10. Demonstrate acceptable MDI administration technique.
  11. eDiary compliance ≥ 70% during screening, defined as completing the daily eDiary and answering "Yes" to taking 2 puffs of run-in BD MDI for any 10 mornings and 10 evenings in the last 14 days prior to randomization.

Exclusion criteria

Exclusion criteria

  1. Life-threatening asthma as defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s).
  2. Any respiratory infection or asthma exacerbation treated with systemic and/or additional ICS treatment in the 8 weeks prior to Visit 1 and throughout the Screening Period.
  3. Hospitalization for asthma within 8 weeks of Visit 1.
  4. Historical or current evidence of a disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neurological, endocrine, gastrointestinal, or pulmonary (eg, active tuberculosis, bronchiectasis, pulmonary eosinophilic syndromes, and ). Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or that could affect the efficacy or safety analysis.
  5. Known history of drug or alcohol abuse within 12 months of Visit 1.
  6. Unresectable cancer that has not been in complete remission for at least 5 years prior to Visit 1. Note: Squamous cell and basal cell carcinomas of the skin are not exclusionary.
  7. Participation in another clinical study with a study intervention administered in the last 30 days or 5 half-lives, whichever is longer. Any other study intervention that is not identified in this protocol is prohibited for use during study duration.
  8. Previous or current randomization into studies within the AEROSPHERE program including KALOS, LOGOS, VATHOS, LITHOS, or any glycopyrronium studies (PT001).
  9. Use of a nebulizer or a home nebulizer for receiving asthma medications. Note: Acute use of a nebulizer for an asthma exacerbation during hospitalization is allowed as long as there is no occurrence within 8 weeks of Visit 1.
  10. Do not meet the stable dosing period prior to Visit 1 or unable to abstain from protocol-defined prohibited medications during Screening and Treatment Periods.
  11. Receipt of COVID-19 vaccine (regardless of vaccine delivery platform, eg, vector, lipid nanoparticle) ≤7 days prior to Visit 1 (from last vaccination or booster dose).
  12. Participants with known to beta2-agonists, corticosteroids, or any component of the MDI.
  13. Any clinically relevant abnormal findings in physical examination, clinical chemistry, hematology, vital signs, or , which in the opinion of the Investigator, may put the participant at risk because of his/her participation in the study.
  14. Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking \< 6 months prior to Visit 1 (including all forms of tobacco, e-cigarettes or other vaping devices, and marijuana).
  15. Planned hospitalization during the study.
  16. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  17. Study Investigators, sub-Investigators, coordinators, and their employees or immediate family members.
  18. Judgment by the Investigator that the participant is unlikely to comply with study procedures, restrictions and requirements.
  19. For women only - currently pregnant (confirmed with positive highly sensitive urine pregnancy test), breast-feeding, or planned pregnancy during the study or not using acceptable measures, as judged by the Investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
374 participants (actual)

Study arms

  • Experimental
    BFF MDI 160/9.6 μg BID (320/19.2μg/day)

    Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), BDI (320/19.2μg/day)

    Drug: BFF MDI 160/9.6 μg BID (320/19.2μg/day)

  • Active comparator
    BD MDI 160 μg BID (320 μg/day)

    Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)

    Drug: BD MDI 160 μg BID (320 μg/day)

Interventions

  • DrugBFF MDI 160/9.6 μg BID (320/19.2μg/day)

    Drug pages: Budesonide · Formoterol

    Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg BID (320/19.2μg/day)

    Also known as: BFF

  • DrugBD MDI 160 μg BID (320 μg/day)

    Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)

    Also known as: BD

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 12

    Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 12. FEV1 AUC0-3 is calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time to report the result in liters. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

    Time frame: At Week 12

Secondary outcomes

  1. Change From Baseline in Morning Pre-dose Trough FEV1 at Week 12

    Change from baseline in morning pre-dose trough FEV1 at Week 12. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

    Time frame: At Week 12

  2. Onset of Action on Day 1: Absolute Change in FEV1 at 5 Minutes on Day 1

    Onset of action on Day 1: Absolute change in FEV1 at 5 minutes on Day 1. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

    Time frame: On Day 1

  3. Change From Baseline in the Mean Number of Puffs of Rescue Medication Use (Puffs/Day) Over 12 Weeks

    Change from baseline in the mean number of puffs of rescue medication use (puffs/day) over 12 Weeks. Baseline is the average during the last 7 days before randomization. Over 12 weeks is the average from randomization up to week 12. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

    Time frame: Over 12 Weeks

  4. Percentage of Responders in ACQ-7 (≥ 0.5 Decrease Equals Response) at Week 12

    Percentage of responders in ACQ-7 at Week 12, where responders are defined as participants with a ≥0.5 decrease in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

    Time frame: At Week 12

  5. Percentage of Responders in ACQ-5 (≥ 0.5 Decrease Equals Response) at Week 12

    Percentage of responders in ACQ-5 at Week 12, where responders are defined as participants with a ≥0.5 decrease in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

    Time frame: At Week 12

  6. Percentage of Responders in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s) +12) (≥ 0.5 Increase Equals Response) at Week 12

    Percentage of responders in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(s)+12) at Week 12, where responders are defined as participants with a ≥0.5 increase in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

    Time frame: At Week 12

  7. Rate of Severe Asthma Exacerbation (Pooled LITHOS and VATHOS Data) During the Treatment Period (up to 24 Weeks)

    As requested by a Health Authority, data from LITHOS and VATHOS (NCT05202262), two studies originally designed to assess lung function, were pooled to analyze the annualized rate of severe asthma exacerbations. This analysis was prespecified, uses data up to 12 weeks for LITHOS and 24 weeks for VATHOS, and was incorporated into the multiple testing procedure. An exacerbation is considered severe if it results in at least one of the following: a course of systemic corticosteroids (SCS) for ≥3 consecutive days to treat symptoms of asthma worsening, an ER or urgent care visit due to asthma requiring treatment with SCS, an in-patient hospitalization due to asthma, or death related to asthma. Treatment policy is implemented to handle all intercurrent events except for initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is used.

    Time frame: 24 Weeks

  8. Rate of Severe Asthma Exacerbation During the Treatment Period (up to 12 Weeks)

    Annualized rate of severe asthma exacerbation during the treatment period (up to 12 Weeks). An asthma exacerbation will be considered severe if it results in at least one of the following: a course of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening, an ER or urgent care visit due to asthma that required treatment with systemic corticosteroids, an in-patient hospitalization due to asthma, or death related to asthma. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

    Time frame: 12 Weeks

07

Results

Posted Jan 28, 2026

Participant flow

Adult and adolescent participants who have asthma which remains inadequately controlled (ACQ-7 total score ≥ 1.5) despite treatment with low dose ICS or ICS/LABA were recruited at 106 sites across 7 countries. Participants were randomized in a 1:1 scheme to BFF MDI 160/9.6 μg or BD MDI 160 μg. Randomization was stratified by baseline asthma treatment and age. The treatment period was 12 weeks in duration with up to 7 in-clinic visits during screening and treatment.

Participant flow — Overall Study
MilestoneBFF MDI 160/9.6 μgBD MDI 160 μg
Started179174
Completed176165
Not completed39
Withdrew: Failure to meet randomization criteria11
Withdrew: Lost to follow-up01
Withdrew: Physician decision01
Withdrew: Withdrawal by subject26

Outcome measures

PrimaryChange From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 12

Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 12. FEV1 AUC0-3 is calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time to report the result in liters. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

Time frame:
At Week 12
Reported as:
Least squares mean · Liter
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 12
LiterBFF MDI 160/9.6 μgBD MDI 160 μg
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 120.309 ± 0.02350.109 ± 0.0241
Statistical analysis
  • BFF MDI 160/9.6 μg vs BD MDI 160 μg · ANCOVA · p = <0.0001 · Mean difference (final values): 0.200 · 95% CI 0.134 to 0.267An increase in estimate favors study drug. The model includes treatment, visit, prior maintenance medication, treatment-by-visit interaction, baseline trough FEV1, and percent Albuterol reversibility.
SecondaryChange From Baseline in Morning Pre-dose Trough FEV1 at Week 12

Change from baseline in morning pre-dose trough FEV1 at Week 12. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

Time frame:
At Week 12
Reported as:
Least squares mean · Liter
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 12
LiterBFF MDI 160/9.6 μgBD MDI 160 μg
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 120.143 ± 0.02210.060 ± 0.0226
Statistical analysis
  • BFF MDI 160/9.6 μg vs BD MDI 160 μg · ANCOVA · p = 0.0096 · Mean difference (final values): 0.082 · 95% CI 0.020 to 0.144An increase in estimate favors study drug. The model includes treatment, visit, prior maintenance medication, treatment-by-visit interaction, baseline trough FEV1, and percent Albuterol reversibility.
SecondaryOnset of Action on Day 1: Absolute Change in FEV1 at 5 Minutes on Day 1

Onset of action on Day 1: Absolute change in FEV1 at 5 minutes on Day 1. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

Time frame:
On Day 1
Reported as:
Least squares mean · Liter
Onset of Action on Day 1: Absolute Change in FEV1 at 5 Minutes on Day 1
LiterBFF MDI 160/9.6 μgBD MDI 160 μg
Onset of Action on Day 1: Absolute Change in FEV1 at 5 Minutes on Day 10.179 ± 0.01380.026 ± 0.0142
Statistical analysis
  • BFF MDI 160/9.6 μg vs BD MDI 160 μg · ANCOVA · p = <0.0001 · Mean difference (final values): 0.153 · 95% CI 0.114 to 0.192An increase in estimate favors study drug. The model includes treatment, timepoint, prior maintenance medication, treatment-by-timepoints interaction, baseline tFEV1, and % Albuterol reversibility.
SecondaryChange From Baseline in the Mean Number of Puffs of Rescue Medication Use (Puffs/Day) Over 12 Weeks

Change from baseline in the mean number of puffs of rescue medication use (puffs/day) over 12 Weeks. Baseline is the average during the last 7 days before randomization. Over 12 weeks is the average from randomization up to week 12. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

Time frame:
Over 12 Weeks
Reported as:
Least squares mean · Puffs/Day
Change From Baseline in the Mean Number of Puffs of Rescue Medication Use (Puffs/Day) Over 12 Weeks
Puffs/DayBFF MDI 160/9.6 μgBD MDI 160 μg
Change From Baseline in the Mean Number of Puffs of Rescue Medication Use (Puffs/Day) Over 12 Weeks-0.589 ± 0.0708-0.309 ± 0.0721
Statistical analysis
  • BFF MDI 160/9.6 μg vs BD MDI 160 μg · ANCOVA · p = 0.0058 · Mean difference (final values): -0.280 · 95% CI -0.478 to -0.082A decrease in estimate favors study drug. The model includes treatment, 4-week interval, their interaction, prior maintenance medication, severe asthma exacerbation history, baseline daily rescue use, baseline tFEV1, and % Albuterol reversibility.
SecondaryPercentage of Responders in ACQ-7 (≥ 0.5 Decrease Equals Response) at Week 12

Percentage of responders in ACQ-7 at Week 12, where responders are defined as participants with a ≥0.5 decrease in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Responders in ACQ-7 (≥ 0.5 Decrease Equals Response) at Week 12
Percentage of participantsBFF MDI 160/9.6 μgBD MDI 160 μg
Percentage of Responders in ACQ-7 (≥ 0.5 Decrease Equals Response) at Week 1274.361.9
Statistical analysis
  • BFF MDI 160/9.6 μg vs BD MDI 160 μg · Regression, Logistic · p = 0.0101 · Odds ratio (or): 1.851 · 95% CI 1.158 to 2.958An odds ratio greater than 1 favors study drug. The model includes treatment, prior maintenance medication, baseline instrument score, baseline tFEV1, and % Albuterol reversibility.
SecondaryPercentage of Responders in ACQ-5 (≥ 0.5 Decrease Equals Response) at Week 12

Percentage of responders in ACQ-5 at Week 12, where responders are defined as participants with a ≥0.5 decrease in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Responders in ACQ-5 (≥ 0.5 Decrease Equals Response) at Week 12
Percentage of participantsBFF MDI 160/9.6 μgBD MDI 160 μg
Percentage of Responders in ACQ-5 (≥ 0.5 Decrease Equals Response) at Week 1277.162.5
Statistical analysis
  • BFF MDI 160/9.6 μg vs BD MDI 160 μg · Regression, Logistic · p = 0.0025 · Odds ratio (or): 2.114 · 95% CI 1.302 to 3.432An odds ratio greater than 1 favors study drug. The model includes treatment, prior maintenance medication, baseline instrument score, baseline tFEV1, and % Albuterol reversibility.
SecondaryPercentage of Responders in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s) +12) (≥ 0.5 Increase Equals Response) at Week 12

Percentage of responders in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(s)+12) at Week 12, where responders are defined as participants with a ≥0.5 increase in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Responders in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s) +12) (≥ 0.5 Increase Equals Response) at Week 12
Percentage of participantsBFF MDI 160/9.6 μgBD MDI 160 μg
Percentage of Responders in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s) +12) (≥ 0.5 Increase Equals Response) at Week 1261.647.5
Statistical analysis
  • BFF MDI 160/9.6 μg vs BD MDI 160 μg · Regression, Logistic · p = 0.0084 · Odds ratio (or): 1.873 · 95% CI 1.175 to 2.985An odds ratio greater than 1 favors study drug. The model includes treatment, prior maintenance medication, baseline instrument score, baseline tFEV1, and % Albuterol reversibility.
SecondaryRate of Severe Asthma Exacerbation (Pooled LITHOS and VATHOS Data) During the Treatment Period (up to 24 Weeks)

As requested by a Health Authority, data from LITHOS and VATHOS (NCT05202262), two studies originally designed to assess lung function, were pooled to analyze the annualized rate of severe asthma exacerbations. This analysis was prespecified, uses data up to 12 weeks for LITHOS and 24 weeks for VATHOS, and was incorporated into the multiple testing procedure. An exacerbation is considered severe if it results in at least one of the following: a course of systemic corticosteroids (SCS) for ≥3 consecutive days to treat symptoms of asthma worsening, an ER or urgent care visit due to asthma requiring treatment with SCS, an in-patient hospitalization due to asthma, or death related to asthma. Treatment policy is implemented to handle all intercurrent events except for initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is used.

Time frame:
24 Weeks
Reported as:
Least squares mean · Exacerbations/year
Rate of Severe Asthma Exacerbation (Pooled LITHOS and VATHOS Data) During the Treatment Period (up to 24 Weeks)
Exacerbations/yearBFF MDI 160/9.6 μg or 320/9.6 μgBD MDI 160 μg or 320 μg
Rate of Severe Asthma Exacerbation (Pooled LITHOS and VATHOS Data) During the Treatment Period (up to 24 Weeks)0.35 ± 0.050.42 ± 0.07
Statistical analysis
  • BFF MDI 160/9.6 μg or 320/9.6 μg vs BD MDI 160 μg or 320 μg · Regression, Negative Binomial · p = 0.3610 · Rate ratio: 0.82 · 95% CI 0.54 to 1.25A rate ratio below 1 favors study drug. The model includes budesonide dose, formoterol dose, study, severe asthma exacerbation history, prior maintenance medications, baseline tFEV1, % Albuterol reversibility, and region.
SecondaryRate of Severe Asthma Exacerbation During the Treatment Period (up to 12 Weeks)

Annualized rate of severe asthma exacerbation during the treatment period (up to 12 Weeks). An asthma exacerbation will be considered severe if it results in at least one of the following: a course of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening, an ER or urgent care visit due to asthma that required treatment with systemic corticosteroids, an in-patient hospitalization due to asthma, or death related to asthma. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.

Time frame:
12 Weeks
Reported as:
Least squares mean · Exacerbations/year
Rate of Severe Asthma Exacerbation During the Treatment Period (up to 12 Weeks)
Exacerbations/yearBFF MDI 160/9.6 μgBD MDI 160 μg
Rate of Severe Asthma Exacerbation During the Treatment Period (up to 12 Weeks)0.25 ± 0.080.52 ± 0.12
Statistical analysis
  • BFF MDI 160/9.6 μg vs BD MDI 160 μg · Regression, Negative Binomial · p = 0.0419 · Rate ratio: 0.48 · 95% CI 0.23 to 0.97A rate ratio lower than 1 favors study drug. The model includes treatment, severe asthma exacerbation history, prior maintenance medications, baseline tFEV1, % Albuterol reversibility, and region.

Adverse events

Collected over From the date of first dose of IP up to and including 1 day following the date of last IP dose, up to 12 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BFF MDI 160/9.6 μg0/179 (0%)0/179 (0%)9/179 (5%)
BD MDI 160 μg0/174 (0%)0/174 (0%)9/174 (5.2%)
Most frequent other events
Most frequent other events
EventBFF MDI 160/9.6 μgBD MDI 160 μg
Upper respiratory tract infectionInfections and infestations6/1795/174
NasopharyngitisInfections and infestations3/1794/174

Baseline characteristics

The Efficacy Set is defined as all participants who are randomized to study intervention and receive any amount of randomized study intervention. It excludes 7 participants who were randomized before or concurrently in another study.

Age, Continuous
Age, Continuous(Years)BFF MDI 160/9.6 μgBD MDI 160 μgTotal
Mean48.8 ± 16.648.0 ± 16.148.4 ± 16.3
Sex: Female, Male
Sex: Female, Male(Participants)BFF MDI 160/9.6 μgBD MDI 160 μgTotal
Female113128241
Male6441105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BFF MDI 160/9.6 μgBD MDI 160 μgTotal
Black or African American151934
Asian273360
White123110233
Other10515
Multiple224
Region of Enrollment
Region of Enrollment(Participants)BFF MDI 160/9.6 μgBD MDI 160 μgTotal
Global — Canada191332
Global — Czech Republic404282
Global — Malaysia459
Global — Philippines111122
Global — South Africa111526
Global — South Korea336
Global — United States8980169
Prior asthma medication
Prior asthma medication(Participants)BFF MDI 160/9.6 μgBD MDI 160 μgTotal
ICS434285
ICS/LABA134127261
Baseline reversibility (%)
Baseline reversibility (%)(Percentage)BFF MDI 160/9.6 μgBD MDI 160 μgTotal
Mean21.8 ± 14.521.0 ± 14.621.4 ± 14.6
Baseline pre-bronchodilator FEV1 (L)
Baseline pre-bronchodilator FEV1 (L)(Liter)BFF MDI 160/9.6 μgBD MDI 160 μgTotal
Mean2.097 ± 0.6302.047 ± 0.6072.073 ± 0.619
08

Study locations

104 sites
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Mesa, Arizona 85213, United States
  • Research Site
    Tucson, Arizona 85745, United States
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Encinitas, California 92024, United States
  • Research Site
    Fresno, California 93720, United States
  • Research Site
    Huntington Beach, California 92647, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Sacramento, California 95823, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    San Jose, California 95117, United States
  • Research Site
    Ventura, California 93003, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Cutler Bay, Florida 33189, United States
  • Research Site
    DeBary, Florida 32713, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Miami, Florida 33155, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Miami, Florida 33175, United States
  • Research Site
    Miami, Florida 33180, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Atlanta, Georgia 30361, United States
  • Research Site
    South Bend, Indiana 46617, United States
  • Research Site
    Lexington, Kentucky 40509, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    White Marsh, Maryland 21162, United States
  • Research Site
    North Dartmouth, Massachusetts 02747, United States
  • Research Site
    Farmington Hills, Michigan 48336, United States
  • Research Site
    Rolla, Missouri 65401, United States
  • Research Site
    St Louis, Missouri 63141, United States
  • Research Site
    Kalispell, Montana 59901, United States
  • Research Site
    Missoula, Montana 59808, United States
  • Research Site
    Bellevue, Nebraska 68123, United States
  • Research Site
    Henderson, Nevada 89052, United States
  • Research Site
    Las Vegas, Nevada 89102, United States
  • Research Site
    North Las Vegas, Nevada 89030, United States
  • Research Site
    Portsmouth, New Hampshire 03801, United States
  • Research Site
    New Windsor, New York 12553, United States
  • Research Site
    Schenectady, New York 12308, United States
  • Research Site
    Fayetteville, North Carolina 28314, United States
  • Research Site
    Raleigh, North Carolina 27607, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Edmond, Oklahoma 73034, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Hatboro, Pennsylvania 19040, United States
  • Research Site
    Pittsburgh, Pennsylvania 15236, United States
  • Research Site
    Austin, Texas 78704, United States
  • Research Site
    Beaumont, Texas 77701, United States
  • Research Site
    Boerne, Texas 78006, United States
  • Research Site
    El Paso, Texas 79912, United States
  • Research Site
    Forney, Texas 75126, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    San Antonio, Texas 78258, United States
  • Research Site
    Victoria, Texas 77901, United States
  • Research Site
    Waco, Texas 76712, United States
  • Research Site
    American Fork, Utah 84003, United States
  • Research Site
    Bountiful, Utah 84010, United States
  • Research Site
    Milwaukee, Wisconsin 53228, United States
  • Research Site
    Kamloops, British Columbia V2C 5T1, Canada
  • Research Site
    Kelowna, British Columbia V1Y 4N7, Canada
  • Research Site
    Penticton, British Columbia V2A 5L5, Canada
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Toronto, Ontario M9V 4B4, Canada
  • Research Site
    Winchester, Ontario K0C 2K0, Canada
  • Research Site
    Windsor, Ontario N8X 2G1, Canada
  • Research Site
    Montreal, Quebec H3M 1L3, Canada
  • Research Site
    Québec, Quebec G1G 3Y8, Canada
  • Research Site
    Québec, Quebec G1V 4W2, Canada
  • Research Site
    Jindřichův Hradec, 377 01, Czechia
  • Research Site
    Louny, 44 001, Czechia
  • Research Site
    Lovosice, 410 02, Czechia
  • Research Site
    Miroslav, 671 72, Czechia
  • Research Site
    Prague, 148 00, Czechia
  • Research Site
    Prague, 190 00, Czechia
  • Research Site
    Teplice, 415 01, Czechia
  • Research Site
    Varnsdorf, 407 47, Czechia
  • Research Site
    Alor Star, 5460, Malaysia
  • Research Site
    George Town, 10450, Malaysia
  • Research Site
    Ipoh, 30990, Malaysia
  • Research Site
    Kajang, 43000, Malaysia
  • Research Site
    Kota Bharu, 15586, Malaysia
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Kuala Terengganu, 20400, Malaysia
  • Research Site
    Sarawak Miri, 98000, Malaysia
  • Research Site
    Seremban, 70300, Malaysia
  • Research Site
    Iloilo City, 5000, Philippines
  • Research Site
    Manila, 1000, Philippines
  • Research Site
    Manila, 1014, Philippines
  • Research Site
    Marilao, 3019, Philippines
  • Research Site
    Durban, 4001, South Africa
  • Research Site
    Durban, 4450, South Africa
  • Research Site
    Newton, 2113, South Africa
  • Research Site
    Pretoria, 0186, South Africa
  • Research Site
    Tygervalley, 7530, South Africa
  • Research Site
    Daegu, 42415, South Korea

Showing the first 100 of 104 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Nov 2024, 20 months.

Results were first posted in Jan 2026, 1 year 2 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 20 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 6, 2023
StartActual
Feb 27, 2023
Primary completionActual
Nov 19, 2024
CompletionActual
Nov 19, 2024
Results first posted
Jan 28, 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05755906
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Feb 27, 2023
Primary completion
Nov 19, 2024
Completion
Nov 19, 2024
Results posted
Jan 28, 2026
Last update
Jan 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion